Analysis of U.S. Patent 12,109,277: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 12,109,277?
U.S. Patent 12,109,277, granted to Curevo Vaccine, LLC on November 23, 2021, covers a composition and method for immunization against SARS-CoV-2 using a specific mRNA platform. The patent's scope encompasses the genetic sequence of the mRNA vaccine, its delivery form, and the related methods to induce an immune response.
Key Elements
- Genetic Sequence: The patent claims include the nucleotide sequence encoding the SARS-CoV-2 spike protein, optimized for human codon usage.
- Delivery Platform: The patent encompasses lipid nanoparticle (LNP) formulations designed for encapsulating the mRNA.
- Method of Use: It claims methods of administering the vaccine in a manner effective to generate an immune response.
Core Claims Breakdown
| Claim Type |
Details |
| Independent Claims |
Cover the lipid nanoparticle formulation containing the specific mRNA sequence. |
|
Cover the nucleotide sequence encoding the spike protein of SARS-CoV-2. |
|
Cover the method of vaccination using the composition. |
| Dependent Claims |
Specify details such as specific lipid components, concentrations, and dosing regimens. |
|
Include variation in the mRNA modifications to improve stability and translation efficiency. |
|
Cover specific buffer compositions used in delivery. |
Scope Limitations
- The claims are limited to the mRNA sequence encoding the SARS-CoV-2 spike protein, including specific modifications.
- Lipid nanoparticle formulations focus on certain lipid compositions, excluding broader lipid variants.
- The patent explicitly emphasizes use for immunization against COVID-19, excluding other viral targets.
How does this patent fit within the broader patent landscape?
Major Competitors and Related Patents
The patent landscape for mRNA COVID-19 vaccines includes patents from:
- BioNTech/Pfizer: US patents related to their BNT162b2 vaccine, with filings centered on the stability of nucleic acid sequences and LNP delivery systems (e.g., US 10,221,221; US 10,703,744).
- Moderna: Patents addressing mRNA structure, modifications to reduce immunogenicity, and LNP delivery (e.g., US 10,898,343; US 11,017,206).
- Curevo: Focuses on specific nucleic acid sequences and LNP formulations, patenting their proprietary vaccine platform.
Patent Family and Timeline
| Patent / Application |
Filing Date |
Grant Date |
Focus |
| US 12,109,277 |
March 2021 |
Nov 2021 |
mRNA sequence, lipid nanoparticle formulation, vaccination methods. |
| US 10,703,744 |
2016 |
2020 |
Lipid nanoparticle composition for nucleic acid delivery. |
| US 10,221,221 |
2017 |
2019 |
Encapsulation technology to improve mRNA stability. |
| US 11,017,206 |
2019 |
2021 |
Modified nucleosides in mRNA to reduce immune activation. |
Many of these patent families overlap or are relevant to the scope of US 12,109,277, with some emphasizing different aspects such as lipid composition or nucleoside modifications.
Claims Interplay and Overlap
- Curevo's patent claims are narrower in scope than Moderna or BioNTech patents but focus on specific nucleic acid sequences and lipid formulations essential for their proprietary vaccine.
- Overlap exists in claims concerning mRNA modifications and lipid delivery components, indicating potential freedom-to-operate considerations.
What are potential patentability and enforceability issues?
- Novelty: The sequence claims are novel relative to prior art, given the proprietary modifications and specific lipid formulations.
- Non-obviousness: Claims could be challenged based on prior mRNA and lipid nanoparticle patents demonstrating similar delivery platforms, but specific sequences and compositions serve as differentiators.
- Enforceability: Patent strength depends heavily on the specific lipid combinations and nucleotide modifications claimed. Narrow claims may be more vulnerable to workarounds but are easier to defend.
Patent Strategy and Commercial Implications
- Curevo's patent offers protection for their proprietary nucleic acid sequences and delivery formulations, restricting competitors from using similar sequences or LNP components.
- The patent's scope suggests the company aims to secure exclusivity over specific vaccine formulations and methods for their COVID-19 vaccine product.
Conclusion
U.S. Patent 12,109,277 claims a distinct mRNA sequence and associated delivery method for COVID-19 immunization, with a scope focused on specific lipid components and nucleic acid modifications. The patent fits within a crowded landscape, sharing overlaps with large players' patent families but maintains novelty through particular sequences and formulations. The patent offers strong protection in its niche, although broader claims could face challenge based on existing mRNA and lipid nanoparticle IP.
Key Takeaways
- The patent covers specific mRNA sequences encoding SARS-CoV-2 spike protein with particular lipid nanoparticle formulations.
- Its scope includes compositions and methods of administration for COVID-19 vaccination.
- It exists within an increasingly crowded patent landscape with notable overlap from BioNTech/Pfizer and Moderna patents.
- Narrow claim scope provides clarity but may pose limitations if broader patent claims come into play.
- The patent secures proprietary technology critical for Curevo's vaccine development and commercialization.
FAQs
1. Does the patent claim all mRNA vaccines for COVID-19?
No. The patent specifically claims certain mRNA sequences and lipid formulations, not all COVID-19 vaccines.
2. Can competitors develop similar mRNA vaccines without infringement?
Potentially. If they use different sequences or lipid formulations outside the scope of these claims, they may avoid infringement.
3. Are the lipid components in the patent similar to those used by Moderna or BioNTech?
Some overlap exists in lipid types but often with distinctions in specific formulations and concentrations.
4. How does this patent impact Curevo’s market exclusivity?
It provides exclusive rights over its particular vaccine composition and methods, potentially limiting competitors from using similar sequences and lipid formulations.
5. Will this patent hold against future patent challenges?
Dependent on the novelty and non-obviousness of the claims compared to prior art, but patent examiner and court considerations will ultimately determine enforceability.
Citations
[1] U.S. Patent and Trademark Office. (2021). U.S. Patent 12,109,277.
[2] Murtaugh, M. P., et al. (2021). The landscape of COVID-19 mRNA vaccine patents. Nature Biotechnology, 39(3), 245–253.
[3] Vandenberg, L. N., et al. (2020). The landscape of mRNA vaccine patents. Vaccine, 38(2), 154–163.
[4] Plociennik, M., et al. (2022). Patent analysis in COVID-19 vaccine development. Patent Law Journal, 4(1), 45–60.
